- Patients
- Clinical Research
- Clinical trials
- Fortitude 102
2022-09-28T00:00:00.000+08:00
Ongoing
Fortitude 102
Fortitude 102
Gastric cancer
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Trial overview
Clinical Area
Medical Oncology |
Disease / Condition
Gastroesophageal |
Study Phase
III
Trial Identifiers
Registration number: NCT05111626 |